Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Essex Bio-TechnologyHKSE:01061 +0.88%86 Days Payable is 15.27 as of Jun. 2026, which is 25% below its 10-year median of 20.32. GuruFocus rates HKSE:01061 with a GF Score™ of 86/100 and a GF Value™ of HK$3.13 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 925 Drug Manufacturers companies, Essex Bio-Technology ranks worse than 95.78% on this metric.
The historical rank and industry rank for Essex Bio-Technology's Days Payable or its related term are showing as below:
HKSE:01061'
s Days Payable Range Over the Past 10 Years
Min: 1.99 Med: 20.32 Max: 96.28
Current: 19.14
During the past 13 years, Essex Bio-Technology's highest Days Payable was 96.28. The lowest was 1.99. And the median was 20.32.
HKSE:01061's Days Payable is ranked worse than 95.78% of 925
companies
in the Drug Manufacturers industry
Industry Median: 88.75
vs HKSE:01061: 19.14
Essex Bio-Technology's Days Payable
declined
from Jun. 2025 (20.03) to Jun. 2026 (15.27).
It may suggest that Essex Bio-Technologyaccelerated paying its suppliers.
The historical data trend for Essex Bio-Technology's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Essex Bio-Technology's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Essex Bio-Technology Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Essex Bio-Technology's Days Payable distribution charts can be found below:
* The bar in red indicates where Essex Bio-Technology's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Essex Bio-Technology's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Essex Bio-Technology (HKSE:01061) has a Days Payable of 15.27 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Essex Bio-Technology and its competitors. This is 25% below median its historical median of 20.32. Over the past decade, Essex Bio-Technology's Days Payable has ranged from 1.99 to 96.28. According to the industry distribution chart, Essex Bio-Technology ranks #886 out of 925 companies in the Drug Manufacturers industry, placing it in the top 95.8%.
Is Essex Bio-Technology's Days Payable too high?
Essex Bio-Technology's current Days Payable of 15.27 is 25% below median its 10-year median of 20.32. Over the past 10 years, this metric has ranged from a low of 1.99 to a high of 96.28. The Drug Manufacturers industry median Days Payable is 88.75. Essex Bio-Technology's value of 15.27 is 82.8% below this industry median. Based on the distribution chart, Essex Bio-Technology ranks #886 out of 925 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Essex Bio-Technology has a GF Score™ of 86/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Essex Bio-Technology's Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Essex Bio-Technology ranks #886 out of 925 companies for Days Payable. This places Essex Bio-Technology in the lower half of its industry. The industry median Days Payable is 88.75. Essex Bio-Technology's value of 15.27 is 82.8% below this benchmark. Historically, Essex Bio-Technology's own Days Payable has ranged from 1.99 to 96.28 over the past decade. While the company's 10-year median is 20.32 vs. the industry median of 88.75, Essex Bio-Technology has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 88.75, based on 925 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Essex Bio-Technology's current Days Payable of 15.27 is 82.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Essex Bio-Technology and its competitors. For the Drug Manufacturers industry, the median Days Payable is 88.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Essex Bio-Technology's current Days Payable is 15.27, which is 25% below median its own 10-year median of 20.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Essex Bio-Technology stock overvalued right now?
Based on GuruFocus' analysis, Essex Bio-Technology (HKSE:01061) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.13, compared to a current price of HK$2.29 — trading 26.8% below its estimated fair value. The current Days Payable is 15.27, which is 25% below median its 10-year median of 20.32 and 82.8% below the Drug Manufacturers industry median of 88.75. Essex Bio-Technology's overall GF Score™ is 86/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Essex Bio-Technology (HKSE:01061), the current Days Payable is 15.27 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Essex Bio-Technology (HKSE:01061) Overvalued in 2026?
Based on GuruFocus' analysis, Essex Bio-Technology stock appears to be undervalued.
The current stock price of HK$2.29 is trading 26.8% below its estimated GF Value™ of HK$3.13.
GuruFocus considers Essex Bio-Technology to be Modestly Undervalued.
Key valuation signals for HKSE:01061:
Days Payable: 15.27 (25% below median its 10-year median of 20.32)
GF Value™: HK$3.13 vs. price of HK$2.29 (26.8% below fair value)
Industry Position: 82.8% below the Drug Manufacturers median (#886 of 925)
No single metric tells the full story. See the HKSE:01061 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Essex Bio-Technology Ltd is principally engaged in investment holding and development, manufacture, and sale of biologic drugs in the People's Republic of China. The company is made up of segments of Ophthalmology products and Surgical products. Its products under Ophthalmology include the Beifushu series, Tobramycin Eye Drops, Levofloxacin Eye Drops, and Sodium Hyaluronate Eye Drops. The products under Surgical include the Beifuji series, Carisolv dental caries removal gel, and mouthwash. The majority of the group's revenue comes from the PRC, also operates in Hong Kong and other countries.
86GF Score
Get the complete analysis for HKSE:01061
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01061 has been successfully added to your 
